Saphnelo approved in the EU for the treatment of moderate to

AstraZeneca’s Saphnelo (anifrolumab) has been approved in the European Union as an add-on therapy for the treatment of adult patients with moderate to severe, active autoantibody-positive systemic lupus erythematosus (SLE), despite receiving standard therapy. Saphnelo is the first biologic for SLE approved in ...

Related Keywords

Canada , Japan , Cambridge , Cambridgeshire , United Kingdom , United States , Netherlands , Amsterdam , Noord Holland , America , British , Ronald Van Vollenhoven , Astrazeneca Saphnelo , Al Sawah , Medarex Inc , European Commission , American College Of Rheumatology , Nasdaq , Astrazeneca , Amsterdam Rheumatology Center , Investor Relations Team , European Union , Lupus Foundation Of America , Medicinal Products , Human Use , European Medicines Agency , Executive Vice President , Bristol Myers Squibb , Uncontrolled Lupus , Interferon Pathway , Based Composite Lupus Assessment , New England Journal , Lancet Rheumatology , Rare Diseases , Disease Control , Systemic Lupus Erythematosus , Lupus Sci , Active Systemic Lupus , Receptor Monoclonal Antibody , Severe Systemic Lupus , Hopkins Lupus , Adult Patients , Lupus Foundation , Ann Rheum , Term Safety , Adult Subjects , Active Systemic Lupus Erythematosus , Arthritis Res , Typei Interferons , Basic Concepts , Clinical Relevance , Immune Mediated Inflammatory ,